Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bathocuproine disulfonic acid (BCS) is a water-soluble, membrane-impermeant copper chelator widely utilized in biochemical and cell biology research. It exhibits high affinity for copper ions, specifically the Cu+ form, sequestering them to prevent their cellular uptake and participation in redox-active processes. In the field of oncology research, BCS is frequently employed as a tool to study and inhibit cuproptosis—a regulated cell death pathway triggered by copper-dependent protein aggregation in the mitochondria. By chelating extracellular copper, BCS can counteract the cytotoxic effects of copper-transporting ionophores such as elesclomol. While it is a standard laboratory reagent for investigating copper homeostasis, it is also used in preclinical models, including acute myeloid leukemia (AML) xenografts, to elucidate the role of copper metabolism in tumor progression and to validate therapeutic targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bathocuproine disulfonic acid.